Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus SOLU CORTEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus SOLU CORTEF.
DEXAMETHASONE vs SOLU-CORTEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Solu-Cortef (hydrocortisone sodium succinate) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including prostaglandins and leukotrienes. It also inhibits immune cell migration and activation.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
100-1000 mg intravenous (IV) or intramuscular (IM), then 100-500 mg IV or IM every 2-6 hours as needed.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal elimination half-life: 1.5-2 hours (hydrocortisone); clinical duration of action is longer due to genomic effects (6-8 hours).
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal: ~80% as metabolites (mainly 17-hydroxycorticosteroids) and <5% unchanged. Biliary/fecal: minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid